Toyonori Tsuzuki
Overview
Explore the profile of Toyonori Tsuzuki including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
277
Citations
2530
Followers
0
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Taoka R, Fukuhara H, Miyake M, Kobayashi K, Ikeda A, Kanao K, et al.
Photodiagnosis Photodyn Ther
. 2025 Mar;
:104554.
PMID: 40086561
Background: This analysis utilized a subject-based analysis of data from the prospective single-arm phase III trial (jRCT2061210055) to evaluate the efficacy of photodynamic diagnosis (PDD) when 5-aminolevulinic acid hydrochloride (5-ALA)...
2.
Tohi Y, Yokomizo A, Kimura T, Wakabayashi M, Shiota M, Mori K, et al.
Int J Clin Oncol
. 2025 Mar;
PMID: 40056276
Background: We have demonstrated that patients with prostate-specific antigen failure following radical prostatectomy benefit from salvage radiation therapy prior to salvage hormone therapy in a multicenter, randomized, open-label, phase 3...
3.
Kato M, Sato H, Naito Y, Yamamoto A, Kawanishi H, Nakano Y, et al.
Int J Clin Oncol
. 2025 Feb;
PMID: 39937427
Background: Intraductal Carcinoma of the Prostate (IDC-P) is a significant prognostic indicator for prostate cancer, which demonstrates significant associations with homologous recombination repair gene mutations (HRRm) and alterations in tumor...
4.
Nagumo Y, Hattori K, Kimura T, Sekino Y, Naiki T, Kobayashi Y, et al.
Int J Radiat Oncol Biol Phys
. 2025 Jan;
PMID: 39755215
Purpose: Bladder preservation therapy in combination with atezolizumab and radiation therapy trial, which was a multicenter, open-label, single-arm phase 2 study, showed a promisingly high interim clinical complete response (cCR)...
5.
Taoka R, Fujimoto K, Inoue K, Tsuzuki T, Oya M, Sugimoto M
Int J Urol
. 2024 Dec;
PMID: 39673232
No abstract available.
6.
Bernhardt M, Weinhold L, Bremmer F, Chan E, Cheng L, Collins K, et al.
Histopathology
. 2024 Nov;
86(4):627-639.
PMID: 39610035
Aims: Tumour content in prostatic biopsies is an important indicator of prostate cancer volume and patient prognosis. Consequently, guidelines typically recommend reporting it as a percentage or linear length (mm)....
7.
Taoka R, Fukuhara H, Miyake M, Kobayashi K, Ikeda A, Kanao K, et al.
Int J Clin Oncol
. 2024 Nov;
30(1):121-122.
PMID: 39560814
No abstract available.
8.
Taoka R, Fukuhara H, Miyake M, Kobayashi K, Ikeda A, Kanao K, et al.
Int J Clin Oncol
. 2024 Oct;
30(1):110-120.
PMID: 39375287
Background: In Japan, the authorized period (2-4 h) between oral administration of 5-aminolevulinic acid hydrochloride (5-ALA) and transurethral resection for non-muscle invasive bladder cancer (NMIBC) may restrict photodynamic diagnosis (PDD)...
9.
Standardization of CD30 immunohistochemistry staining among three automated immunostaining platforms
Seki M, Satou A, Funato R, Tamaki T, Wada N, Nakada N, et al.
Pathol Int
. 2024 Aug;
74(9):530-537.
PMID: 39171823
The identification of CD30 expression by immunohistochemistry is essential for the treatment of lymphomas using an antibody-drug conjugate targeting CD30. However, no standardized protocol for CD30 staining has been available....
10.
Kato S, Koshino A, Lasota J, Komura M, Wang C, Ebi M, et al.
Appl Immunohistochem Mol Morphol
. 2024 Jul;
32(8):362-370.
PMID: 39076030
SATB2 has been reported to be highly specific for lower gastrointestinal tract tumors. On the basis of its ileum-colon conversion effects, which involve the activation of colonic genes in cooperation...